KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to -$31.1 million.

  • Travere Therapeutics' Change in Accured Expenses rose 728.47% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 189.46%. This contributed to the annual value of -$31.1 million for FY2024, which is 225.43% down from last year.
  • As of FY2024, Travere Therapeutics' Change in Accured Expenses stood at -$31.1 million, which was down 225.43% from $24.8 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Change in Accured Expenses registered a high of $24.8 million during FY2023, and its lowest value of -$31.1 million during FY2024.
  • Over the past 3 years, Travere Therapeutics' median Change in Accured Expenses value was $22.2 million (recorded in 2022), while the average stood at $5.3 million.
  • Per our database at Business Quant, Travere Therapeutics' Change in Accured Expenses surged by 277.59% in 2021 and then plummeted by 225.43% in 2024.
  • Over the past 5 years, Travere Therapeutics' Change in Accured Expenses (Yearly) stood at $4.4 million in 2020, then soared by 277.59% to $16.7 million in 2021, then spiked by 33.00% to $22.2 million in 2022, then rose by 11.64% to $24.8 million in 2023, then tumbled by 225.43% to -$31.1 million in 2024.